Pegbio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies, focusing on peptide and small molecule drugs for chronic diseases. Its primary areas of expertise are metabolic disorders, including type 2 diabetes, obesity, non-alcoholic steatohepatitis, and rare endocrine conditions like congenital hyperinsulinemia. Pegbio’s development pipeline features a core product, PB-119, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, targeted at improving glycemic control and weight management. Additional candidates in its portfolio address indications such as gout, opioid-induced constipation, and related metabolic ailments. The company combines proprietary technology in polyethylene glycol (PEG) modification and peptide engineering to enhance the efficacy and stability of its therapeutic agents. Pegbio’s approach to drug development positions it at the intersection of growing demand for chronic disease treatments and advancements in biologic drug technologies, contributing to the expansion of options for patients with lifestyle-related and metabolic disorders.